Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Partners In Pain With Xenon

This article was originally published in The Pink Sheet Daily

Executive Summary

As part of its burgeoning efforts in neuroscience, Genentech will discover and develop compounds and companion diagnostics for the treatment of pain, not an area the company historically has played in.


Related Content

Xenon Progresses Antisense Anemia Drug In Pact With Isis
Xenon Feels No Pain After $41M Upfront From Teva
Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
Huge Market Belies The Long And Difficult Road To Novel Pain Therapies
Next For Genentech: Tackling Neuroscience And Infectious Disease


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts